Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy EyeGate Pharmaceuticals (EYEG) stocks in Canada

Learn how to easily invest in EyeGate Pharmaceuticals stocks.

EyeGate Pharmaceuticals is a biotechnology business based in the US. EyeGate Pharmaceuticals stocks (EYEG.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.74 – the same closing value as a week prior. EyeGate Pharmaceuticals employs 14 staff and has a trailing 12-month revenue of around $12,059.

How to buy shares in EyeGate Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – EYEG – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Is it a good time to buy EyeGate Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

How has Coronavirus impacted EyeGate Pharmaceuticals's stock price?

Since the stock market crash in March caused by coronavirus, EyeGate Pharmaceuticals's stock price has had significant negative movement.

Its last market close was $1, which is 86.11% down on its pre-crash value of $7.2 and 250.00% down on the lowest point reached during the March crash when the stocks fell as low as $3.5.

If you had bought $1,000 worth of EyeGate Pharmaceuticals stocks at the start of February 2020, those stocks would have been worth $620.01 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $166.67.

EyeGate Pharmaceuticals stock price (NASDAQ:EYEG)

Use our graph to track the performance of EYEG stocks over time.

EyeGate Pharmaceuticals shares at a glance

Information last updated 2022-01-09.
Latest market close$1.00
52-week range$0.80 - $7.85
50-day moving average $1.86
200-day moving average $3.47
Wall St. target price$11.83
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.63

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Feature Table description
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks (total value up to $9,000) when you deposit and trade $150.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of at least $200/month. Valid until March 1, 2022.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.

Compare up to 4 providers

Online stock trading

EyeGate Pharmaceuticals price performance over time

Historical closes compared with the close of $1 from 2022-01-07

1 week (2022-01-05) N/A
1 month (2021-12-15) 11.41%
3 months (2021-10-15) -48.45%
6 months (2021-07-16) -69.42%
1 year (2021-01-15) -83.95%
2 years (2020-01-15) -86.03%
3 years (2019-01-15) 82.22%
5 years (2017-01-13) 1.56

EyeGate Pharmaceuticals financials

Revenue TTM $12,059
Gross profit TTM $-3,553,986
Return on assets TTM -40.35%
Return on equity TTM -103.8%
Profit margin 0%
Book value $1.47
Market capitalisation $24.7 million

TTM: trailing 12 months

EyeGate Pharmaceuticals share dividends

We're not expecting EyeGate Pharmaceuticals to pay a dividend over the next 12 months.

Have EyeGate Pharmaceuticals's shares ever split?

EyeGate Pharmaceuticals's shares were split on a 1:15 basis on 29 August 2019. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your EyeGate Pharmaceuticals shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for EyeGate Pharmaceuticals shares which in turn could have impacted EyeGate Pharmaceuticals's share price.

EyeGate Pharmaceuticals share price volatility

Over the last 12 months, EyeGate Pharmaceuticals's shares have ranged in value from as little as $0.8002 up to $7.85. A popular way to gauge a stock's volatility is its "beta".

EYEG.US volatility(beta: 0.8)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while EyeGate Pharmaceuticals's is 0.7974. This would suggest that EyeGate Pharmaceuticals's shares are less volatile than average (for this exchange).

EyeGate Pharmaceuticals overview

EyeGate Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company, focuses on developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system in the United States. It develops PP-001, a clinical stage dihydroorotate dehydrogenase inhibitor that has been developed in two clinical-stage ophthalmic formulations, consisting of PaniJect that is in Phase Ia/IIb clinical trial for multiple diseases that affect the posterior region of the eye, including non-infectious posterior uveitis and diabetic macular edema; and PaniDrop, which is in Phase I safety study for multiple diseases that affect the ocular surface and anterior region of the eye, comprising of allergic conjunctivitis, viral conjunctivitis, and dry eye disease. The company also develops ocular bandage gel, a modified form of the natural polymer hyaluronic acid for corneal wound repair, and punctate epitheliopathies with a focus on dry eye. The company has license agreements with BioTime, Inc. Eyegate Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Waltham, Massachusetts.

Frequently asked questions

EyeGate Pharmaceuticals in the news

There are no recent company news
Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site